VEGFRs Predict Bevacizumab Benefit in Advanced Non Small Cell Lung Cancer

NCT01891708 | Unknown DMC

• 1 other identifier: XHZL02
• Study Type: observational
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

a. VEGFRs may be the biomarker which can predict the effect of bevacizumab in non small cell lung cancer

Conditions

Non Small Cell Lung Cancer; Brain Metastasis

Outcome Measures

Primary Outcomes (1)

• PFS

  6 months

Secondary Outcomes (1)

• OS

  18 months

Interventions

bevacizumab, standard chemotherapy and radiation OTHER

the dose and application model of the three intervention are not specified by the sponsor who just observe the efficacy of the combination application of the three in non small cell lung cancer patients with brain metastasis once enrolled.

Also known as: Drug:bevacizumab,also Avastine, Drug:standard chemotherapy recommended by clinical guidlines, Radiation

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

advanced non small cell lung cancer patients with brain metastatic disease

You may qualify if:

• non squamous cell non small cell lung cancer
• with measurable disease
• ECOG 0-1

You may not qualify if:

• \- patients received surgery in recent 4 weeks

Sponsors & Collaborators

• Li Liu: lead

Study Sites (1)

Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, 430071, China

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

peripheral blood

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung; Brain Neoplasms

Interventions

Bevacizumab; Radiation

Condition Hierarchy (Ancestors)

Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Central Nervous System Neoplasms; Nervous System Neoplasms; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins; Physical Phenomena

Study Officials

• Li Liu, MD

  Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Li Liu, MD

CONTACT

027-85872015; liulixiehe@163.com

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Target Duration: 2 Months
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: June 19, 2013
• First Posted: July 3, 2013
• Study Start: June 1, 2013
• Primary Completion: December 1, 2014
• Study Completion: December 1, 2018
• Last Updated: July 3, 2013

Record last verified: 2013-07

Locations

CN (1)